These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 5487541)

  • 1. The chemotactic activity for neutrophil and eosinophil leucocytes of the trimolecular complex of the fifth, sixth and seventh components of human complement (C567) prepared in free solution by the 'reactive lysis' procedure.
    Lachmann PJ; Kay AB; Thompson RA
    Immunology; 1970 Dec; 19(6):895-9. PubMed ID: 5487541
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activation of the complement attack mechanism in the fluid phase and its control by C567-INH: lysis of normal erythrocytes initiated by zymosan, endotoxin, and immune complexes.
    Lint TF; Behrends CL; Baker PJ; Gewurz H
    J Immunol; 1976 Nov; 117(5 Pt 1):1440-6. PubMed ID: 1002985
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Studies of the inhibition of C56-initiated lysis (reactive lysis). IV. Antagonism of the inhibitory activity c567-INH by poly-L-lysine.
    McLeod B; Baker P; Behrends C; Gewurz H
    Immunology; 1975 Feb; 28(2):379-90. PubMed ID: 47309
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complement-mediated lysis of liposomes produced by the reactive lysis procedure.
    Lachmann PJ; Munn EA; Weissmanng
    Immunology; 1970 Dec; 19(6):983-6. PubMed ID: 5530596
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reactions of nascent C567 (reactive lysis).
    Goldman JN
    Transplant Proc; 1974 Mar; 6(1):21-5. PubMed ID: 4817055
    [No Abstract]   [Full Text] [Related]  

  • 6. Complement-derived leukotactic factors in inflammatory synovial fluids of humans.
    Ward PA; Zvaifler NJ
    J Clin Invest; 1971 Mar; 50(3):606-16. PubMed ID: 5545123
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Studies on the inhibition of C56-initiated lysis (reactive lysis). III. Characterization of the inhibitory activity C567-INH and its mode of action.
    McLeod B; Baker P; Gewurz H
    Immunology; 1975 Jan; 28(1):133-49. PubMed ID: 1116868
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective attraction of eosinophils and synergism between eosinophil chemotactic factor of anaphylaxis (ECF-A) and a fragment cleaved from the fifth component of complement (C5a).
    Kay AB; Shin HS; Austen KF
    Immunology; 1973 Jun; 24(6):969-76. PubMed ID: 4123965
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Studies on the inhibition of C56-initiated lysis (reactive lysis). II. C567-INH--an inhibitor of the C567 trimolecular complex of complement.
    McLeod BC; Baker P; Gewurz H
    Int Arch Allergy Appl Immunol; 1974; 47(4):623-32. PubMed ID: 4415956
    [No Abstract]   [Full Text] [Related]  

  • 10. Mediation of leukocyte components of inflammatory reactions by lipoxygenase products of arachidonic acid.
    Goetzl EJ; Goldman DW; Naccache PH; Sha'afi RI; Pickett WC
    Adv Prostaglandin Thromboxane Leukot Res; 1982; 9():273-82. PubMed ID: 6283846
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reaction mechanisms of nascent C567 (reactive lysis). I. Reaction characteristics for production of EC567 and lysis by C8 and C9.
    Goldman JN; Ruddy S; Austen KF
    J Immunol; 1972 Aug; 109(2):353-9. PubMed ID: 4558539
    [No Abstract]   [Full Text] [Related]  

  • 12. [Genetically controlled disorders of the human complement system].
    Brackertz D
    Schweiz Med Wochenschr; 1974 Jun; 104(22):777-84. PubMed ID: 4135190
    [No Abstract]   [Full Text] [Related]  

  • 13. Reactive lysis: the complement-mediated lysis of unsensitized cells. II. The characterization of activated reactor as C56 and the participation of C8 and C9.
    Lachmann PJ; Thompson RA
    J Exp Med; 1970 Apr; 131(4):643-57. PubMed ID: 4193935
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Studies on chemotaxis. 13. Differences in the chemotactic responses of neutrophil and eosinophil polymorphonuclear leucocytes.
    Keller HU; Sorkin E
    Int Arch Allergy Appl Immunol; 1969; 35(3):279-87. PubMed ID: 4885559
    [No Abstract]   [Full Text] [Related]  

  • 15. Ultrastructure of membrane lesions in immune lysis, osmotic lysis and drug-induced lysis.
    Seeman P
    Fed Proc; 1974 Oct; 33(10):2116-24. PubMed ID: 4607618
    [No Abstract]   [Full Text] [Related]  

  • 16. [Clinical importance of the complement system].
    Spath P; Huber H
    Wien Klin Wochenschr; 1973 Jun; 85(25):445-50. PubMed ID: 4123223
    [No Abstract]   [Full Text] [Related]  

  • 17. The effects of an ECF-A and formyl methionyl chemotactic peptides on oxidative metabolism of human eosinophils and neutrophils.
    Beswick PH; Kay AB
    Clin Exp Immunol; 1981 Feb; 43(2):399-407. PubMed ID: 6268337
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemotactic factor-induced enhancement of the binding of human immunoglobulin classes and subclasses to neutrophils and eosinophils.
    Kay AB; Walsh GM
    Clin Exp Immunol; 1984 Sep; 57(3):729-34. PubMed ID: 6088141
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trichophyton rubrum and the chemotaxis of polymorphonuclear leucocytes.
    Davies RR; Zaini F
    Sabouraudia; 1984; 22(1):65-71. PubMed ID: 6701724
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Contrasting responses to multiple chemotactic stimuli in transendothelial migration: heterologous desensitization in neutrophils and augmentation of migration in eosinophils.
    Kitayama J; Carr MW; Roth SJ; Buccola J; Springer TA
    J Immunol; 1997 Mar; 158(5):2340-9. PubMed ID: 9036983
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.